About 100 reports

The US has one of the most liberal approaches to OTC distribution in the world.

  • Gastrointestinal Drug
  • OTC
  • United States
  • Demand

Constipation is a common functional gastrointestinal (GI) disorder that is most prevalent in the elderly and female population.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology

GERD is one of the regularly watched intermittent gastrointestinal disorders around the world.

  • Gastrointestinal Drug
  • North America
  • South America
  • United States
  • Market Size

GASTROINTESTINAL (GI) DISORDERS ##. ##. ##.

  • Gastrointestinal Drug
  • North America
  • United States
  • Market Size
  • MicroBiome Therapeutics LLC

GERD is one of the commonly observed recurrent gastrointestinal disorders worldwide.

  • Gastrointestinal Drug
  • OTC
  • Therapy
  • United States
  • Market Size
  • Gastrointestinal Drugs
  • Six: Gastrointestinal Drugs

Chapter Six: Gastrointestinal Drugs Figure ##-## U. S.

  • Gastrointestinal Drug
  • United States
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Clinical Trial profile. 125 Trial Title
  • Clinical Trial profile. 319 Trial Title

CSP Gastrointestinal Duodenal Ulcer, Gastric Ulcers Planned Phase I Interventional lansoprazole Zhejiang Jinhua CONBA Bio-pharm Co Ltd ## ## Randomized, Open, Double-cycle Crossover, Fasting Bioequivalence Trial of Pantoprazole Sodium Enteric-coated Tablets and Pantoloc in H

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • World
  • Clinical Trial profile. 7 Trial Title
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Takeda Pharmaceutical Company Limited
  • Target
  • Clinical Trial profile. 15 Trial Title

Pylori Negative Healthy Volunteers GDCT## GDC##, ## Gastrointestinal Acidity, Unspecified Gastrointestinal Disorders Completed Phase I Interventional (aspirin DR + omeprazole) Aralez Pharmaceuticals Inc ## May 2012 ## ## ## Potassium Transporting ATPase Alpha Cha

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative

Zentiva' s key product groups include anti-infection products and medicines for cardiovascular disease, pain, central nervous system disorders, female healthcare and gastrointestinal diseases.

  • Gastrointestinal Drug
  • Sleep Aid
  • Romania
  • Demand
  • Zentiva NV
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF TRAVELER'S DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF TRAVELER'S DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS

## ## ## ## ## ## Germany ## ## ## ## ## ## Japan ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## Italy ## ## ## ## ## ## Canada Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a tim

  • Drug Development
  • Gastrointestinal Drug
  • Healthcare
  • World
  • Product Initiative
  • PROPORTION OF DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2019*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Drug Development
  • Gastrointestinal Drug
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Clinical Trial profile. 190 Trial Title
  • Official Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Gastrointestinal Drug
  • Therapy
  • World
  • Merck & Co., Inc.
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF ACID INDIGESTION (HEARTBURN/PYROSIS) TO GASTROINTESTINAL CLINICAL TRIALS
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF ACID INDIGESTION (HEARTBURN/PYROSIS) TO GASTROINTESTINAL CLINICAL TRIALS

## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## ## France Source: GlobalData' s Pharma Intelligence Cen

  • Clinical Trial
  • Gastrointestinal Drug
  • OTC
  • World
  • Product Initiative
  • Target
  • Clinical Trial profile. 240 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2018* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO

  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative
  • Takeda Pharmaceutical Company Limited
  • PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2019*
  • PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%), 2019*

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Clinical Trial profile. 635 Trial Title
  • Clinical Trial profile. 825 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • 8.2 Lubiprostone
  • 8.5 Rifaximin

The company is involved in research and development for developing new treatments for gastrointestinal and cardiorenal diseases To develop therapeutics for cardiorenal and gastrointestinal diseases ##. ## Astellas Pharma, Inc. ## ##. ##. ## C o m p a n y O v e r v i e

  • Gastrointestinal Drug
  • North America
  • United States
  • World
  • Market Size
  • APR 19, 2017: REDHILL BIOPHARMA TO HOST R&D DAY ON BEKINDA FOR ACUTE GASTROENTERITIS AND IBS-D
  • OCT 14, 2015: REDHILL BIOPHARMA PROVIDES UPDATE ON BEKINDA ONGOING PHASE III STUDY FOR GASTROENTERITIS AND ANNOUNCES PLANNED PHASE II STUDY FOR IBS-D

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Vaccine
  • United States
  • Product Initiative
  • Target
  • Target

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Clinical Trial profile. 303 Trial Title
  • Clinical Trial profile. 465 Trial Title

Menarini Industrie Farmaceutiche Riunite Srl Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2018 2018 trials are taken as of May 2018 ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Clinical Trial
  • Gastrointestinal Drug
  • Pharmaceutical
  • Therapy
  • World

By Clinical Trial Stages: The report provides Gastrointestinal Disorders pipeline molecules by clinical trial stages including both early and late stage development - phase ## clinical trials, phase ## clinical trials, phase ## clinical trials, preclinical research, and discovery stag

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • World
  • PROPORTION OF REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%),
  • PROPORTION OF REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%),

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Clinical Trial profile. 255 Trial Title
  • Clinical Trial profile. 130 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Merck & Co., Inc.
  • NARONAPRIDE - DRUG PROFILE
  • MAR 23, 2016: IRONWOOD PHARMACEUTICALS INITIATES PHASE IIB CLINICAL TRIAL OF IW-3718 IN REFRACTORY GASTRO ESOPHAGEAL REFLUX DISEASE

Patients were randomly assigned to one of two arms - one arm received Insegia alone, the other arm received placebo.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • ASTRAZENECA ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH IRONWOOD PHARMA FOR LINACLOTIDE
  • SYNERGY PHARMA ENTERS INTO AGREEMENT WITH IRONWOOD PHARMA FOR PLECANATIDE

Linaclotide Delayed Release-## (DR##).

  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Company Financials
  • Ironwood Pharmaceuticals, Inc.
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF INFECTIOUS DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS
  • PROPORTION OF INFECTIOUS DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2017*

The prominent features of this report are - ##.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • World
  • Product Initiative
  • APR 19, 2017: REDHILL BIOPHARMA TO HOST R&D DAY ON BEKINDA FOR ACUTE GASTROENTERITIS AND IBS-D
  • OCT 14, 2015: REDHILL BIOPHARMA PROVIDES UPDATE ON BEKINDA ONGOING PHASE III STUDY FOR GASTROENTERITIS AND ANNOUNCES PLANNED PHASE II STUDY FOR IBS-D

IBS IS ONE OF THE MOST COMMON GASTROINTESTINAL DISORDERS.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • RedHill Biopharma Ltd.